{
    "nctId": "NCT02761642",
    "briefTitle": "A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon\u00ae) in Anemic Participants With Breast Cancer Undergoing Chemotherapy",
    "officialTitle": "Multicenter Study for the Evaluation of Efficacy and Safety of NeoRecormon\u00ae Therapy Administered as 30000 IU Subcutaneously in Anemic Patients With Breast Cancer Treated With Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Anemia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Percentage of Participants With Response to Treatment Based on Hemoglobin Levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult female participants with histological diagnosis of breast cancer\n* Any type of chemotherapy planned for greater than or equal to (\\>/=) 9 weeks\n* Hemoglobin level less than (\\<) 11 grams per deciliter (g/dL)\n* Participants able to receive iron supplement, if necessary\n\nExclusion Criteria:\n\n* Known or suspected contraindications to epoetin beta\n* Pregnancy or lactation period\n* Diagnosis of anemia only due to iron-deficiency\n* Diagnosis of thalasemic syndromes\n* Epilepsy and/or cerebral metastasis\n* Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}